Clinical trial · Interventional
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma
NCT00563927CI-TRIAL-00003642unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Squamous Cell | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Nasopharyngeal Neoplasms | Nasopharyngeal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-fluorouracil | Drug | Fluorouracil | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Conventional RT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Failure free survival rate
- timeFrame
- 5 year
Secondary outcomes (3)
- measure
- Disease-specific survival rate
- timeFrame
- 5-year
- measure
- Overall survival rate
- timeFrame
- 5-year
- measure
- Complication-free rates
- timeFrame
- 5-year
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Undifferentiated or non-keratinizing carcinoma * Tumor staged as N2-3 * No evidence of distant metastasis M0 * Performance status:0-2 * Marrow: WBC \>= 4 and platelet \>= 100 * Renal: creatinine clearance \>= 60 * Informed consent Exclusion Criteria: * WHO type I squamous cell carcinoma or adenocarcinoma * Age \>= 70 * Palliative intent or tumor extent mandating AP opposing facio-cervical fields * Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years * Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume * Previous chemotherapy * Patient is pregnant or lactating
References
Publications (0)
Data not yet available
No reference posted for this study.